Key points are not available for this paper at this time.
Ambrosia Biosciences has launched with a 16 million series A financing round led by BVF Partners and Boulder Ventures. Ambrosia researchers are developing small-molecule, GLP-1–based drugs for metabolic disorders and weight loss. The compounds will target incretins and class B G protein-coupled receptors, but the company is not ready to elaborate much more, according to Nick Traggis, the president and chief operating officer. Ambrosia's 15-person scientific staff is composed almost entirely of former Array BioPharma employees who Pfizer laid off when they closed their research facility in Boulder, Colorado, in June of this year. "That's an incredibly large world-class group of medicinal chemists and biologists that were made available to the market, " Traggis says. The company raised a stealth seed round in March, but now the official launch comes just 5 months later. Traggis says the Array closure "really poured the gasoline on the fire for us to be able
Sarah Braner (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: